MINERVA NEUROSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.48 USD | -0.80% |
|
-0.80% | -59.67% |
| Feb. 27 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
| Feb. 27 | Top Midday Decliners | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17.34M |
|---|---|---|---|---|---|
| Net income 2024 * | -32M | Net income 2025 * | -54M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.69
x | P/E ratio 2025 * |
-0.55
x | Employees | 9 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Minerva Neurosciences, Inc.
More recommendations
More press releases
| 1 day | -0.80% | ||
| 1 week | -0.80% | ||
| Current month | -3.88% | ||
| 1 month | -6.42% | ||
| 3 months | -67.07% | ||
| 6 months | -53.38% | ||
| Current year | -59.67% |
1 week
2.29
2.80
1 month
2.292.80
Current year
2.2913.49
1 year
2.2613.49
3 years
1.2628.28
5 years
1.26121.72
10 years
1.26126.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 14-02-28 | |
Geoff Race
FOU | Founder | 63 | 10-06-30 |
Fred Ahlholm
DFI | Director of Finance/CFO | 58 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeryl Hilleman
BRD | Director/Board Member | 66 | 18-07-16 |
Jan van Heek
BRD | Director/Board Member | 75 | 14-06-30 |
| Director/Board Member | 68 | 17-12-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 2.48 | -0.80% | 11,384 |
| 24-04-18 | 2.5 | +1.21% | 14,482 |
| 24-04-17 | 2.47 | -1.20% | 15,676 |
| 24-04-16 | 2.5 | +3.31% | 68,670 |
| 24-04-15 | 2.42 | -3.20% | 30,363 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.5
USD
Average target price
11
USD
Spread / Average Target
+340.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -59.67% | 17.48M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- NERV Stock
